Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2013

Ichihara Eiki, Hotta Katsuyuki, Takigawa Nagio, Kudo Kenichiro, Kato Yuka, Honda Yoshihiro, Hayakawa Hiromi, Minami Daisuke, Sato Akiko, Tabata Masahiro, Tanimoto Mitsune, Kiura Katsuyuki

Abstract excerpt

Gefitinib is an essential drug for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations. The approved dosage is 250 mg/body/day without adjustment for physical size such as body surface area (BSA), and the impact of physical size on the efficacy of gefitinib has not been evaluated. Here, we sought to clarify this issue using a retrospective cohort. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Body Size

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Gefitinib

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 23809059
DOI: 10.1016/j.lungcan.2013.05.021

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.PMID 23809059Read ↗

Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703.Semantic proximity Read ↗

Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation.Semantic proximity Read ↗

Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area.Semantic proximity Read ↗

Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment.Semantic proximity Read ↗

Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.Semantic proximity Read ↗

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib.Semantic proximity Read ↗

Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?Semantic proximity Read ↗

Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.Semantic proximity Read ↗

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.